KLK3 and prostate carcinoma: In total 26,548 men were included in the final cohort (<80 years, with clinically localized prostate cancer (cT1-2cN0M0), PSA ≤ 20 ng/mL, biopsy GG ≤ 2 with percent positive cores (PPC) ≤ 33% who underwent RP and had surgical pathology available).